VIRALEZE™ UK COVID-19 Clinical Study Completes Recruitment
Posted: 26 September 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has completed recruitment for the post-market clinical study of its broad-spectrum antiviral barrier nasal spray, VIRALEZE™, in patients with COVID-19 in the UK. Recruitment proceeded rapidly…
WEHI discovery leads to clinical trial for rare women’s cancers
Posted: 26 September 2023 An international clinical trial exploring a new way to treat rare and aggressive gynaecological cancers has launched in Melbourne. Based on a WEHI-led discovery, the trial hopes to enhance treatment options for women with…
NEO-BIONICA APPOINTS ULI GOMMEL AS CHIEF TECHNOLOGY OFFICER
Posted: 26 September 2023 Neo-Bionica, a leading innovator in the field of medical device development and manufacturing, is thrilled to announce the appointment of Uli Gommel as its new Chief Technology Officer (CTO). Uli will lead Neo-Bionica’s technology…
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Posted: 26 September 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the regulatory authorization of eftilagimod alpha (“efti”) manufactured at…
Platform Expansion: Breast Cancer Diagnostic Test Update
Posted: 26 September 2023 Rhythm Biosciences Ltd (ASX: RHY) (“Rhythm” or the “Company”) is pleased to provide an update on its cancer diagnostics technology platform expansion program in breast cancer. As previously announced (ASX: RHY – 19 June…
BioCurate and Takeda Renew Alliance to Accelerate Discoveries of New Drugs and Therapeutics
Posted: 26 September 2023 Partnership enables collaboration in high-quality therapy development programs. BioCurate, the independently-operated joint venture between The University of Melbourne and Monash University, today announced the renewal of its partnership with and Takeda to identify and collaborate on…
Researchers discover genes behind antibiotic resistance in deadly superbug infections
Posted: 26 September 2023 Australian researchers have uncovered new genetic insights into Staphylococcus aureus, revealing what makes the bacterium so dangerous when it enters the blood. While common, Staphylococcus aureus infections – known as Golden staph – can be life-threatening…
Australian-made cancer drug gets billion-dollar US FDA approval
Posted: 25 September 2023 A drug invented in Melbourne to treat a lethal bone marrow cancer is set to become a billion-dollar global blockbuster after US regulators on Friday gave it the green light to be sold there. Momelotinib was…
New research paper: Brain stimulation shows promise as a potential treatment for Alzheimer’s
Posted: 25 September 2023 The Bionics Institute’s Professor Kate Hoy has published a pioneering new research paper showing changes in brain activity and cognitive function in Alzheimer’s disease patients following six weeks of a patterned form of magnetic…
Optiscan Correlates with Histology in Breast Study
Posted: 21 September 2023 Optiscan Imaging Limited (ASX: OIL) is pleased to provide an interim readout on its Breast Cancer Intraoperative Assessment Study. The Study, currently being undertaken at the Royal Melbourne, Frances Perry and Epworth Hospitals, involves…
New Milestone For Moderna Vaccine Facility
Posted: 19 September 2023 Thanks to the Andrews Labor Government, Victorians are one step closer to locally manufactured mRNA vaccines and medicines, with construction of Moderna’s mRNA vaccine manufacturing facility reaching the halfway mark, ahead of schedule. Minister…
New Major Asthma Partnership with US-Based SENTA Partners
Posted: 19 September 2023 Adherium Limited (ASX: ADR), a leading digital health company specialising in remote patient monitoring and data solutions for respiratory patients, confirms a new transformative partnership in which SENTA Partners has agreed on a plan…
